Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00387920
Other study ID # NCI-2009-00361
Secondary ID NCI-2009-00361CD
Status Completed
Phase Phase 1
First received October 12, 2006
Last updated January 27, 2014
Start date October 2006

Study information

Verified date January 2014
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I trial is studying the side effects and best dose of sunitinib in treating young patients with refractory solid tumors. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.


Description:

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose (MTD) and recommended phase II dose of sunitinib malate in pediatric patients with refractory solid tumors.

II. Determine the toxicity of this regimen in these patients. III. Characterize the pharmacokinetics of this regimen in these patients. IV. Evaluate the tolerability and pharmacokinetic profile of sunitinib malate capsule contents sprinkled over applesauce or yogurt using the recommended phase II dose.

SECONDARY OBJECTIVES:

I. Determine, preliminarily, the antitumor effects of this regimen in these patients.

II. Describe changes in peripheral blood monocyte counts, circulating endothelial cells, and plasma angiogenic factors during treatment with sunitinib malate.

III. Explore changes in tumor vascular permeability using dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in patients receiving sunitinib malate.

OUTLINE: This is a multicenter, dose-escalation study (part A) followed by a pediatric-friendly formulation study (part B).

PART A: Patients receive oral sunitinib malate once daily on days 1-28 days. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of sunitinib malate until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

PART B: Patients receive sunitinib malate capsule contents sprinkled over applesauce or yogurt once daily on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. After the first course, patients may switch to capsule formulation for convenience.

NOTE: Patients will not receive sunitinib malate on day 2 of the first course to allow for pharmacokinetic testing.

Blood is collected on days 1, 7, 14, 21, and 28 of course 1 for pharmacokinetic studies using liquid chromatography/mass spectrometry.

After completion of study treatment, patients are followed up for 30 days.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 21 Years
Eligibility Inclusion Criteria:

- Histologically confirmed solid tumor (not required for patients with intrinsic brain stem tumors or optic pathway gliomas)

- Recurrent or refractory disease

- Measurable or evaluable disease

- No known curative therapy or therapy proven to prolong survival with an acceptable quality of life exists

- Patients with metastatic bone marrow disease are eligible but are not evaluable for hematologic toxicity

- Must not be refractory to red blood cell or platelet transfusions

- Primary CNS tumors or known CNS metastases allowed

- Neurological deficits must have been relatively stable for = 1 week before study enrollment

- No imaging evidence of prior intracranial hemorrhage

- No evidence of new CNS hemorrhage on baseline MRI obtained within 14 days before study enrollment (ECHO gradient MRI sequences per institutional guidelines required for evaluation of CNS hemorrhage)

- The presence of small punctuate CNS hemorrhage on these scans will exclude a patient from participation

- No known bone marrow metastatic disease

- No tumors involving the pleural surface

- Karnofsky performance status (PS) 50-100% (> 10 years of age) OR Lansky PS 50-100% (= 10 years of age)

- Absolute neutrophil count = 1,000/mm³*

- Platelet count = 100,000/mm³ (transfusion independent)*

- Hemoglobin = 8.0 g/dL (transfusions allowed)*

- Creatinine clearance or radioisotope glomerular filtration rate = 70 mL/min OR creatinine based on age/gender as follows:

- No greater than 0.8 mg/dL (2 to 5 years of age)

- No greater than 1 mg/dL (6 to 9 years of age)

- No greater than 1.2 mg/dL (10 to 12 years of age)

- No greater than 1.5 mg/dL (male) OR 1.4 mg/dL (female) (13 to 15 years of age)

- No greater than 1.7 mg/dL (male) OR 1.4 mg/dL (female) (= 16 years of age)

- Bilirubin = 1.5 times upper limit of normal (ULN)

- ALT and AST = 2.5 times ULN (= 5 times ULN for liver metastases)

- Albumin = 2 g/dL

- LVEF or shortening fraction normal

- Corrected QT interval = 450 msec

- Amylase = 1.5 times ULN

- Lipase = 1.5 times ULN

- Body surface area = 0.5 m² (= 0.4 m² for part B)

- Blood pressure within ULN

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No uncontrolled infection

- Able to swallow sunitinib malate capsules (part A only)

- No pre-existing thyroid abnormality (hyper- or hypothyroidism) with unstable thyroid function

- No prior CNS hemorrhage

- No history of allergic reaction attributed to sunitinib malate or component of sunitinib malate capsules

- No allergy to both applesauce and yogurt (part B only)

- Recovered from prior therapy

- No prior sunitinib malate

- No prior anthracycline (any dose)

- No prior radiotherapy to a radiation field that included the heart(including total body or craniospinal irradiation)

- At least 3 months since prior stem cell transplantation or rescue (without total-body irradiation) and no evidence of graft-vs-host disease

- At least 2 weeks since prior local, palliative, small-port radiotherapy (at least 6 months for radiation to = 50% of pelvis)

- At least 6 weeks since other prior substantial bone marrow radiotherapy

- At least 3 weeks since prior myelosuppressive therapy (6 weeks for nitrosoureas)

- At least 1 week since prior antineoplastic biologic agents

- At least 1 week since prior and no concurrent hematopoietic growth factors

- At least 12 days since prior and no concurrent CYP3A4 inducers, including any of the following:

- Rifampin

- Rifabutin

- Carbamazepine

- Phenobarbital

- Phenytoin

- Hypericum perforatum (St. John's wort)

- Efavirenz

- Tipranavir

- At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following:

- Azole antifungals (e.g., itraconazole or ketoconazole)

- Clarithromycin

- Erythromycin

- Diltiazem

- Verapamil

- HIV protease inhibitors (e.g., indinavir, saquinavir, ritonavir, atazanavir, or nelfinavir)

- Delavirdine

- No more than 1 concurrent antihypertensive agent

- No concurrent major surgery

- No concurrent antithrombotic or antiplatelet agents, including any of the following:

- Warfarin

- Heparin

- Low molecular weight heparin

- Acetylsalicylic acid (aspirin)

- Ibuprofen

- Other nonsteroidal anti-inflammatory drugs

- No concurrent medication for the treatment of hypertension

- No other concurrent investigational drugs

- No other concurrent anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Central Nervous System Metastases
  • Childhood Central Nervous System Choriocarcinoma
  • Childhood Central Nervous System Embryonal Tumor
  • Childhood Central Nervous System Germ Cell Tumor
  • Childhood Central Nervous System Germinoma
  • Childhood Central Nervous System Mixed Germ Cell Tumor
  • Childhood Central Nervous System Teratoma
  • Childhood Central Nervous System Yolk Sac Tumor
  • Choriocarcinoma
  • Neoplasms
  • Neoplasms, Germ Cell and Embryonal
  • Recurrent Childhood Central Nervous System Embryonal Tumor
  • Unspecified Childhood Solid Tumor, Protocol Specific

Intervention

Drug:
sunitinib malate
Given orally
Other:
pharmacological study
Correlative studies
Procedure:
dynamic contrast-enhanced magnetic resonance imaging
Undergo DCE-MRI
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
Canada Centre Hospitalier Universitaire Sainte-Justine Montreal Quebec
Canada Hospital for Sick Children Toronto Ontario
United States C S Mott Children's Hospital Ann Arbor Michigan
United States University of Alabama at Birmingham Birmingham Alabama
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States University of Texas Southwestern Medical Center Dallas Texas
United States Baylor College of Medicine Houston Texas
United States Columbia University Medical Center New York New York
United States Childrens Hospital of Orange County Orange California
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania
United States Washington University School of Medicine Saint Louis Missouri
United States UCSF-Mount Zion San Francisco California
United States University of California San Francisco Medical Center-Parnassus San Francisco California
United States Seattle Children's Hospital Seattle Washington
United States Children's National Medical Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary MTD and recommended phase II dose MTD will be the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT). During course 1 of therapy Yes
Primary Adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 Weekly during course 1, assessed up to 35 days Yes
Primary Pharmacokinetics of sunitinib malate using liquid spectrometry/mass spectroscopy methods At baseline and days 1, 7, 14, 21, and 28 of course 1 No
Primary Tolerability and pharmacokinetic profile of capsule contents sprinkled over applesauce or yogurt At baseline and days 1, 7, 14, 21, and 28 of course 1 No
Secondary Correlative studies The laboratory, radiology, and pathology correlative studies are largely expected to be exploratory. Mean and median values will be reported at each time point for circulating endothelial cells, monocyte count, plasma angiogenic markers, and DCE-MRI vascular permeability. Depending on the distribution of data, either the paired t-test or Wilcoxon signed rank test will be used to evaluate for statistically significant changes in these markers from pre-treatment to post-treatment. Days 1 and 28 of course 1 No
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT01164163 - INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Phase 1
Terminated NCT00949117 - Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer Phase 2
Completed NCT00985868 - AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors Phase 1
Completed NCT00281944 - Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors Phase 1
Completed NCT00253474 - PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma Phase 1
Recruiting NCT00084695 - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Phase 2
Completed NCT00053963 - FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Phase 1
Completed NCT00003070 - Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer Phase 3
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00016861 - Irinotecan in Treating Children With Refractory or Progressive Solid Tumors Phase 1
Completed NCT00003754 - Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers Phase 2
Completed NCT00004005 - Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin Phase 2
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Recruiting NCT00898794 - Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer N/A
Terminated NCT00429702 - Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy Phase 2
Completed NCT00459238 - Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants N/A
Completed NCT00138216 - Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Phase 1
Terminated NCT00176540 - Dextromethorphan in Treating Patients With Fatigue Caused by Cancer N/A
Completed NCT00070473 - Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors Phase 1